2020 was a rollercoaster year for the biopharma industry. It was also the year the entire industry changed; from a global response to a worldwide pandemic and an unprecedented effort around vaccine development, consideration of a new drug development model, and the emergence of new opportunities that will continue to propel the industry forward. Podcast host Bob Coughlin and his guests, Jeremy Levin, Chairman and Chief Executive Officer at Ovid Therapeutics; and Nina Kjellson, General Partner at Canaan Partners, discuss the impact of the past year and the challenges and opportunities for 2021. To learn more, go to MassBio.org.
The COVID-19 pandemic remains the number one health concern around the globe as we await approval of multiple vaccines. There are still many unanswered questions and challenges that lie ahead for the biopharma industry, health stakeholders, and government, particularly around development, prioritization, and distribution of the vaccines. Podcast host Bob Coughlin and his guests, Clement Lewin, Head of BARDA Office & New Vaccines at Sanofi Pasteur, and Dr. Kelly Moore, Associate Director of the Immunization Action Coalition & Adjunct Associate Professor at Vanderbilt University Medical Center, discuss these timely issues. To learn more, go to MassBio.org.
COVID-19 has put a spotlight on health inequities in our country, with minority populations being impactd at a disproportionate rate. In this episode, host Bob Coughlin and his guests, Kate Walsh, President and CEO at Boston Medical Center and Chirfi Guindo, Executive Vice President, Head of Global Product Strategy & Commercialization at Biogen
will discuss the challenges facing the biopharma industry and how industry partners and providers can work together to overcome these acute health challenges. To Learn more, visit massbio.org.
Dr. Michelle McMurry-Heath, President & CEO of BIO, and John Maraganore, CEO of Alnylam, join Bob Coughlin, President & CEO of MassBio and a leading voice for the biotechnology industry, to discuss the biopharma industry’s response to COVID-19, its efforts to reduce health inequities, and more.
In this episode, the three shed light on the biopharma industry’s incredible efforts in developing potential tests, treatments, and vaccines for COVID-19, and what that means for patients, future drug development research, and the perception of the industry. They also examine the disparity of care for minority populations and how the industry should respond to that need; clinically, socially, and culturally.
The State of Possible is more than a catchy business slogan. It’s both a vision and call to action from the Massachusetts Biotechnology Council. And now it’s also a podcast. The State of Possible Podcast with Bob Coughlin is a new, monthly podcast featuring MassBio’s President and CEO in thought-provoking conversation with some of the biopharma industry’s leading minds and voices. Each month, Bob and his guests will delve into those issues that are critical to the industry and our culture; offering their unique perspectives on everything from public health policy, to the challenges of drug development, and beyond. Join us in the discussion. To learn more, go to massbio.org.